A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

RedDress Raises $26 Million to Give Patients the Power to Heal Chronic Wounds Using Their Own Blood

RedDress, a personalized and autologous wound management solution created from patients own blood, today announced that it has raised a $26 million Series D round with participation from ATHOS Biopharma GmbH, and other life science investors including Investors Group of HCS Capital and the Ragnar Crossover Fund. The new proceeds will support increased adoption of its product suite, establishment of global partnerships, and the expansion of RedDress’ proprietary blood-based technology to treat more conditions. The latest investment round brings total funding for RedDress to $43M.

Blood clots are the body’s natural way of healing, yet when it comes to chronic wounds from diabetes and other conditions, blood is unable to reach these areas to begin the coagulation and healing process. The first line of defense in treating chronic wounds has always been bandages, negative pressure and specialized dressings. Skin substitutes, a heavily overcrowded market, is another approach, but are very costly and are non-autologous. Between fifteen to twenty-five percent (15-25%) of the US diabetic population gets diabetic ulcers annually, which translates to 1.5 million diabetic wounds per year. The average wound costs the government $12-$15k per wound to treat and if amputation is required, there is an 85% mortality rate after the procedure. The costs to government-run medical programs and to patients themselves is unsustainable.

RedDress has pioneered a proprietary blood-based technology to treat chronic wounds that has almost zero risk of rejection and is far more cost effective. Its ActiGraft product family is an autologous, point-of-care wound management solution that creates  – in real-time – an in-vitro blood clot from patients’ own whole blood. Once applied to the wound, the blood clot jump-starts the wound healing process, serves as a protective covering, and optimizes the body’s own healing potential. The ActiGraft product family can be used for a wide variety of chronic wounds including diabetic and neuropathic ulcers, venous ulcers, pressure injuries, traumatic wounds, post-surgical wounds, skin tears, surgical wounds and more.

“Healing is in our blood, and we are grateful for the continued support from our investors as we advance our mission of supplying healthcare providers with an effective solution to treat chronic and complex wounds through an innovative system that harnesses the power of patient’s own blood,” said Alon Kushnir, CEO and co-founder at RedDress. “This latest funding round further validates the efficacy and strong market performance of the ActiGraft system and provides us with critical resources to expand our autologous, blood-based wound care solutions so we can continue to develop new innovations in other healthcare fields.”

Since RedDress received FDA clearance and a CE Mark in 2020, ActiGraft has helped over 6,000 patients across the spectrum of healthcare facilities in the United States and 39 other countries.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy